[go: up one dir, main page]

Hamano et al., 2011 - Google Patents

TNF by inducing co-stimulatory TNF receptor superfamily members TNFR2, 4-1BB and OX40 augments the number and function of mouse CD4+ FoxP3+ regulatory T …

Hamano et al., 2011

View HTML
Document ID
17265709779991592845
Author
Hamano R
Huang J
Yoshimura T
Oppenheim J
Chen X
Publication year
Publication venue
European journal of immunology

External Links

Snippet

TNF is a pleiotropic cytokine with intriguing biphasic pro-inflammatory and anti-inflammatory effects. Our previous studies demonstrated that TNF up-regulated FoxP3 expression and activated and expanded CD4+ FoxP3+ regulatory T cells (Tregs) by utilizing TNFR2. Further …
Continue reading at pmc.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Hamano et al. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4‐1BB and OX40
Hatzioannou et al. Regulatory T cells in autoimmunity and cancer: a duplicitous lifestyle
Zhang et al. In vivo expansion of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke
Hirota et al. Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis
Yan et al. Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential
Ralainirina et al. Control of NK cell functions by CD4+ CD25+ regulatory T cells
Chen et al. Glucocorticoid amplifies IL‐2‐dependent expansion of functional FoxP3+ CD4+ CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE
Chen et al. TNF-α: an activator of CD4+ FoxP3+ TNFR2+ regulatory T cells
Marçais et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells
Zheng et al. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupus-like syndrome
Zeiser et al. Pathogenesis of acute graft‐versus‐host disease: from intestinal microbiota alterations to donor T cell activation
Zorn et al. Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease
Mizui et al. Targeting regulatory T cells to treat patients with systemic lupus erythematosus
Taylor et al. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40: CD40L costimulatory pathway results in the generation of a potent immune regulatory cell
Ardolino et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Choileain et al. Enhanced regulatory T cell activity is an element of the host response to injury
Goodman et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells
Takeda et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells
Wolf et al. Novel treatment concepts for graft-versus-host disease
King et al. Cutting edge: IL-12 induces CD4+ CD25− T cell activation in the presence of T regulatory cells
Fiocco et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept
Yokoyama et al. IL-2–anti–IL-2 monoclonal antibody immune complexes inhibit collagen-induced arthritis by augmenting regulatory T cell functions
Mai et al. IL-7 receptor blockade following T cell depletion promotes long-term allograft survival
Singh et al. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB× NZW) F1 mice by differentially regulating Foxp3 and PD1 molecules
Liu et al. Suppression of allograft rejection by CD8+ CD122+ PD-1+ Tregs is dictated by their Fas ligand-initiated killing of effector T cells versus Fas-mediated own apoptosis